Comment: This antibody is conjugated to tetraxetan (DOTA) which acts as a chelating agent for the radioisotope yttrium 90. This antibody conjugate is a radioimmunotherapy agent designed for the treatment of pancreatic cancer [6].
Figure 5 from patent US7282567 [3] provides an approximate IC50 of 1nM for humanised PAM4 (clone 475.1A2), as measured by competition binding between chimeric and humanised PAM4 antibodies.
